New antidepressant drugs: Beyond monoaminergic mechanisms

Current Pharmaceutical Design

Volumn 15, Issue 14, 2009, Pages 1559-1562

  Álamo, Cecilio ^a   López Muñoz, Francisco ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMPA RECEPTOR AGONIST; ANTIDEPRESSANT AGENT; APREPITANT; BUPRENORPHINE; CITALOPRAM; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; DULOXETINE; ENDOCANNABINOID; FLUOXETINE; G PROTEIN COUPLED RECEPTOR KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; IMIPRAMINE; IPRONIAZID; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN; OPIATE; PAROXETINE; PHOSPHODIESTERASE IV; REBOXETINE; ROLIPRAM; SEROTONIN; SERTRALINE; SUBSTANCE P; UNINDEXED DRUG; VENLAFAXINE; BIOGENIC AMINE; MONOAMINE OXIDASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; DEPRESSION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; EDITORIAL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NAUSEA; NEUROMODULATION; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR DOWN REGULATION; SEROTONINERGIC SYSTEM; SYNAPTIC TRANSMISSION; VOMITING; ANIMAL; DRUG DELIVERY SYSTEM; FEMALE; MALE; METABOLISM; NOTE; PATHOPHYSIOLOGY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MONOAMINE OXIDASE INHIBITORS;

EID: 67650633000     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788168047     Document Type: Editorial

References (19)

1. World Health Organization. Depression. Available at: www.who.int/ mediacentre.http://www.who.int/mental_health/management/depression/ definition/en/. [Accessed on Jan 7, 2009].
2. ESEMeD/MHEDEA 2000. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004; 420: 21-27.
3. Martín-Águeda B, López-Muñoz F, Rubio G, García-García P, Silva A, Álamo C. Current situation of depression healthcare in Spain: Results of a psychiatrists' survey. Eur J Psychiat 2006; 20: 211-223.
4. López-Muñoz F, Álamo C, Guerra JA, Rubio G. Twenty-four years of scientific publications on selective serotonin reuptake inhibitors (SSRI): A bibliometric approach. In: Shirley AC Ed, Focus on serotonin uptake inhibitor research. New Cork: Nova Science Publishers, Inc. 2006; 191-219.
5. López-Muñoz F, Alamo C. Monoaminergic neurotransmission: The history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009; 15(14): 1563-1586.
6. Álamo C, López-Muñoz F, Armada MJ. Agomelatina: Un nuevo enfoque farmacológico en el tratamiento de la depresión con traducción clínica. Psiq Biol 2008; 15: 125-139.
7. Álamo C, López-Muñoz F, Martín B, Cuenca E. Biología de la depresion y del tratamiento antidepresivo: Mirando al futuro. In: Pichot P Ed, Diagnóstico diferencial y racionalización del tratamiento psicofarmacológico. Madrid: Aula Médica 2001; 87-124.
8. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137-151.
9. Bourin M, Prica C. Melatonin receptor agonist agomelatine: A new drug for treating unipolar depression. Curr Pharm Des 2009; 15(14): 1675-1682.
10. Álamo C, Cuenca E, López-Muñoz F. Avances en psicofarmacología y perspectivas de futuro. In: Avendaño MC, Tamargo J Eds, Nuevos avances en Medicamentos, Monografía XV. Madrid: Real Academia Nacional de Farmacia (Instituto de España) 2004; 351-431.
11. Golan M, Schreiber G, Avissar S. Antidepressants, β-arrestins and GRKs: From regulation of signal desensitization to intracellular multifunctional adaptor functions. Curr Pharm Des 2009; 15(14): 1699-1708.
12. Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 2009; 15(14): 1688-1698.
13. Valdez GR. CRF receptors as a potential target in the development of novel pharmacotherapies for depression. Curr Pharm Des 2009; 15(14): 1587-1594.
14. Nishida A, Miyaoka T, Inagaki T, Horiguchi J. New approaches to antidepressant drug design: Cytokine-regulated pathways. Curr Pharm Des 2009; 15(14): 1683-1687.
15. Thakker-Varia S, Alder J. Neuropeptides in depression: Role of VGF. Behav Brain Res 2009; 197: 262-278.
16. Machado-Vieira R, Salvadore G, Ibrahim LA, Díaz-Granados N, Zarate CA. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des 2009; 15(14): 1595-1611.
17. Ebner K, Sartori SB, Singewald N. Tachykinin receptors as therapeutic targets in stresss-related disorders. Curr Pharm Des 2009; 15(14): 1647-1674.
18. Rodríguez-Bambico F, Duranti A, Tontini A, Tarzia G, Gobbi G. Endocannabinoids in the treatment of mood disorders: Evidence from animal models. Curr Pharm Des 2009; 15(14): 1623-1646.
19. Berrocoso E, Sánchez-Blázquez P, Garzón J, Micó JA. Opiates as antidepressants. Curr Pharm Des 2009; 15(14): 1612-1622.